Welcome
Announcement (4/8/2013)
In response to growing demand in rapid turn-around sequencing applications such as microbial sequencing, amplicon sequencing, ChIPSeq, small RNA Sequencing, and targeted re-sequencing, the CCCB is proudly to offer the Illumina MiSeq System starting from April 8th, 2013. We offer the following sequencing configurations: Single End 50 bp, Paired End 150 bp, and Paired End 250 bp. Please contact us for further information.
__________________________________________________________
Welcome to the Center for Cancer Computational Biology (CCCB) at the Dana-Farber Cancer Institute. The CCCB has three primary elements..
The CCCB sequencing facility offers a wide range of services to assist in the design and execution of next-generation sequencing projects. Utilizing the Illumina (Solexa) sequencing technology, we currently support a number of applications inlcuding ChIP-Seq, RNA-Seq, whole genome, whole exome, and targeted re-sequencing.
The analytical services and support platform aims to provide state-of-the-art assistance in the collection, management, analysis, and interpretation of large-scale data with a focus on data generated using 'omic technologies. In addition, we offer software, services, and training designed to assist investigators in advancing their research.
The CCCB research program is focused on development of new methods for improving analysis and interpretation of genomic data through integration of diverse data types with the goal of creating open-source software tools to be made freely-available to the research community.
__________________________________________________________
CCCB Presents: Monthly Employee Profiles!
Each month, a different CCCB employee will be profiled for the front page of our website. Each month the profiles will cycle off to the 'Members' page as new ones are added.
Kshithija Nagulapalli
Bioinformatics Analyst
Kshithija works as a bioinformatics analyst at the CCCB; her previous research at Indiana University on gene signatures in Colon Adenocarcinoma makes her a qualified employee at the CCCB while giving her the opportunity to learn about cutting edge advancements in the field. Having access to sequencing software allows Kshithija to process flowcells, oversee analysis pipelines, and generate data for clients. Additionally, Kshithija works on consulting projects with fellow bioinformatics analysts. The work they do includes analyzing differential gene expressions, next generation sequencing data analysis, pathway studies, and copy number analysis. Given the extensive work Kshithija does for the CCCB, it may come as a surprise that she maintains a life outside of work! You’ll find Kshithija cooking Indian food and watching the Patriots during football season. Furthermore, this is Kshithija’s first summer in Boston; the city is lucky to have her!
_______________________________________________________

DFCI Intranet Photo of the Week: We are proud as Fieda Abderazzaq poses for Dana-Farber's photo of the week (June 13, 2011). The photo shows Fieda preparing a DNA sample for a procedure known as quantitative polymerase chain reaction, which indicates how many copies of a section of DNA are present.
____________________________________________________________
Mick Correll receives Excellence in Management Award, May 2 2011
We are thrilled to announce that Executive Leadership has selected Mick Correll, Associate Director of the CCCB, as the recipient for the quarterly Excellence in Management Award. This selection was based on numerous nominations regarding Mick's ability to create an ideal work environment through his commitment to staff development/mentoring, professionalism and leadership. Congratulations Mick!
![]()


Mission
The mission of the Center for Cancer Computational Biology (CCCB) is to further the Dana-Farber Cancer Institute's commitment to advance the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases.
We aim to do that by providing broad-based support for the analysis and interpretation of 'omic data and in doing so, further basic, clinical, and translational research and to conduct research that opens new ways of understanding human cancer.

